Furthermore, Sung et al., studied the role of another synthetic drug Bortezomib (PS-341) (SL.4, Table 2) against HIF-1α in Hep3B (human hepatoma), ARH77 (human multiple myeloma), and U299 (human multiple myeloma) cell lines [206]. This evidence concerns the gene HIF1A and hepatocellular carcinoma.